Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity.
about
A small-animal pharmacokinetic/pharmacodynamic PET study of central serotonin 1A receptor occupancy by a potential therapeutic agent for overactive bladder3-Methylcholanthrene (3-MC) and 4-chlorobiphenyl (PCB3) genotoxicity is gender-related in Fischer 344 transgenic rats.Gender-based differences in pharmacokinetics in laboratory animal models.Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations.Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury.Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse.Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.Cardiovascular MRI in small animals.A Toxicologist's Guide to the Preclinical Assessment of Hepatic Microsomal Enzyme Induction.Effectiveness of the liver micronucleus assay using juvenile mice.Toxicological evaluation and metabolism of two N-alkyl benzamide umami flavour compounds: N-(heptan-4-yl)benzo[d][1,3]dioxole-5-carboxamide and (R)-N-(1-methoxy-4-methylpentan-2-yl)-3,4-dimethylbenzamideToxicological evaluation of a novel umami flavour compound: 2-(((3-(2,3-Dimethoxyphenyl)-1H-1,2,4-triazol-5-yl)thio)methyl)pyridine.Toxicological evaluation of two novel bitter modifying flavour compounds: 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione and 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxyToxicological evaluation of a novel cooling compound: 2-(4-methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(2-thienylmethyl)acetamideDaikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawalPharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.Effects of combined quercetin and coenzyme Q(10) treatment on oxidative stress in normal and diabetic rats.Cytochrome P-4503A1 catalyzes the formation of MA1 from territrem a in liver microsomes of 7-week-old female Wistar rats.Metabolism of territrem B and C in liver microsomes from 14-wk-old Wistar rats is catalyzed by cytochrome P-450 3A.Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite).Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats.Pharmacokinetics, tissue distribution and excretion of verticinone from F. hupehensis in rats.In vivo and in vitro evidence of the sex-dependent pharmacokinetics and disposition of G004, a potential hypoglycemic agent, in rats.Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan.Sex differences in pharmacokinetics of cilostazol in rats.Comparative Metabolism of Mequindox in Liver Microsomes, Hepatocytes, and Intestinal Microflora of Chicken
P2860
Q28533727-283739F3-4B26-4FC0-9D98-A4DFFE7971D7Q34172982-F243A652-1682-41E1-AD04-EC9074D5BAE0Q34327917-CA1C369F-F5E4-407E-BC10-271DBA7D56F5Q34392874-C30AF445-C1FE-4747-8823-A6D27A3DDB88Q36027841-331960ED-F4C9-43C6-800E-6126D0B72102Q36061821-2F8B5D68-8B1E-4A7C-A355-62C756AE39BBQ36157925-6C68509C-5994-4D29-885C-E820EA74D1FDQ36330185-5430F4A0-59E0-4F34-B4D5-BD5B5CF85883Q36753612-80155986-B411-4411-A910-CAB53B2D024BQ36943606-486EF18B-5EF8-4DF5-8024-39B60F9A15A4Q37656278-DB166BFF-C321-4709-8CBC-3081E80E0BBCQ37658729-99B938E8-613D-4383-B4A3-AF9AA013BED8Q41435931-B17BBB8B-86D1-4A8A-A9D7-57BD5A33E19AQ41679211-AEF7F3B5-50CE-47F8-AC70-BD62F1440EF9Q41679451-8A622010-1A60-4F08-BEFF-61C867E6723DQ41679566-BE34B16E-2C20-4A09-94AB-00EED2F1A1D0Q41679934-13DDEDDA-FCEB-4B15-9C22-D91EE137B42EQ42285679-FECB9756-AB97-4461-A75D-CE706614749BQ43736160-4678C90F-B234-4548-8C44-89CADC1084FAQ44145979-BAED9A54-28C8-475B-8543-083A66B743B2Q44415413-2D1FFC57-CC86-4C17-AFB3-EEFBC9CDA85BQ46411979-C4641C2D-87AB-487C-9A80-0CDBDB19E48EQ47133712-ECE235D2-43D3-4EE0-BC39-9740B408DC33Q47140600-454F5918-C78C-40BD-8E76-90FDD45B7578Q48410617-529BDCB2-1A15-45DF-A6CD-7646B4F04C41Q51149388-3C76FE09-9400-438A-964C-70E8867B6C24Q51364738-A5C892E7-A276-4019-8414-4857EA985662Q51443735-15186552-7EFC-4D0C-B8AE-ECCAC1690521Q58267085-0CD8F6CF-8604-45AE-BDF7-BC03B0C4FBCA
P2860
Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@ast
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@en
type
label
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@ast
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@en
prefLabel
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@ast
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@en
P1433
P1476
Sex-specific cytochrome P450 a ...... differences in drug toxicity.
@en
P2093
P304
P356
10.1016/0378-4274(92)90245-F
P478
64-65 Spec No
P577
1992-12-01T00:00:00Z